0912 GMT - Strong growth posted by Chinese online healthcare platforms in the past two years could be softer this year, though it's unlikely to be a concern for Alibaba Health Information Technology and JD Health, say HSBC analysts in a note. Online platforms have been gaining drug sales market share as more sales are taking place outside of hospitals, they say. They expect the prescription outflow to sustain growth for these platforms. HSBC lifts its target price for Alibaba Health to HK$6.50 from HK$6.00, but maintains a hold rating as its current valuation has priced in the company's recent artificial-intelligence developments. It raises its target price for JD Health to HK$77.50 from HK$75.50 on updated foreign exchange updates and retains a buy rating. Alibaba Health closed at HK$6.14 while JD Health ended at HK$60.25. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

February 10, 2026 04:12 ET (09:12 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.